cytosine has been researched along with Cancer of Prostate in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In addition, mean residual tumor weights (expressed in grams) after 20-22 days were: Group 1, 12." | 5.30 | Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma. ( Bridges, P; Brown, J; Di Domenico, D; Guinan, P; Lievano, G; Rubenstein, M; Shaw, M, 1997) |
| "AR is also a critical mediator of prostate cancer promotion, conferring growth signals to prostate cancer cells throughout the natural history of the disease." | 2.41 | Molecular biology of the androgen receptor. ( Gelmann, EP, 2002) |
| "Prognostic tools for prostate cancer (PC) are inadequate and new molecular biomarkers may improve risk stratification." | 1.48 | Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. ( Borre, M; Høyer, S; Lynnerup, AS; Storebjerg, TM; Strand, SH; Sørensen, KD; Ørntoft, TF, 2018) |
| "Current diagnostic tools for prostate cancer lack specificity and sensitivity for detecting very early lesions." | 1.46 | Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. ( Absher, DM; Brooks, JD; Burwell, TC; Cooper, SJ; Davis, NS; Gulzar, ZG; Gunther, DS; Kirby, MK; Lasseigne, BN; Myers, RM; Ramaker, RC; Roberts, BS, 2017) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| "The formation or progression of prostate cancer is presumed to be associated with a polymorphism of the vascular endothelial growth factor (VEGF) gene." | 1.32 | Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. ( Chen, HY; Chen, WC; Lin, CC; Tsai, FJ; Wu, HC, 2003) |
| "Nuclear extracts from PC-3 and DU-145 prostate cancer cell lines are defective in the incision of 8-oxoG, 5OHC and thymine glycol (TG) relative to the non-malignant prostate cell line." | 1.32 | Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145. ( Dizdaroglu, M; Evans, MK; Jaruga, P; Lohani, A; Nyaga, SG; Trzeciak, AR, 2004) |
| "In the prostate cancer lines where MT-I was suppressed, glutathione-S-transferase-pi (GST-pi) was expressed." | 1.31 | Suppression of metallothionein-I/II expression and its probable molecular mechanisms. ( Ghoshal, K; Jacob, ST; Majumder, S, 2002) |
| "In contrast, Du145 and PC3 prostate cancer cells express the GSTP1 gene and exhibit methylated and unmethylated GSTP1 alleles." | 1.31 | Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. ( Bashambu, M; Singal, R; van Wert, J, 2001) |
| "A troxacitabine-resistant prostate cancer subline (DU145(R); 6300-fold) that exhibited reduced uptake of troxacitabine was cross-resistant to both gemcitabine (350-fold) and cytarabine (300-fold)." | 1.31 | Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. ( Cass, CE; Clarke, ML; Gourdeau, H; Jolivet, J; Lafrenière, RG; Lee, N; Mackey, JR; Mowles, D; Ouellet, F; Richard, A; Selner, M; Young, JD, 2001) |
| "Bropirimine is an oral immunostimulant found to have efficacy in human transitional cell carcinoma in situ following the initial discovery of its antitumor activity against the murine bladder cancer MBT-2." | 1.30 | Oral bropirimine immunotherapy of rodent prostate cancer. ( Sarosdy, MF, 1997) |
| "In addition, mean residual tumor weights (expressed in grams) after 20-22 days were: Group 1, 12." | 1.30 | Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma. ( Bridges, P; Brown, J; Di Domenico, D; Guinan, P; Lievano, G; Rubenstein, M; Shaw, M, 1997) |
| "Established prostate cancer-derived cell lines LnCAP, DU-145, and PC-3 demonstrated NQO1 wild-type genotype." | 1.30 | 609 C --> T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. ( Borkowsi, M; Hillenbrand, M; Schuff-Werner, P; Seiter, H; Steiner, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 9 (32.14) | 18.2507 |
| 2000's | 11 (39.29) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Gakis, G | 1 |
| Perner, S | 1 |
| Stenzl, A | 1 |
| Renninger, M | 1 |
| Kirby, MK | 1 |
| Ramaker, RC | 1 |
| Roberts, BS | 1 |
| Lasseigne, BN | 1 |
| Gunther, DS | 1 |
| Burwell, TC | 1 |
| Davis, NS | 1 |
| Gulzar, ZG | 1 |
| Absher, DM | 1 |
| Cooper, SJ | 1 |
| Brooks, JD | 1 |
| Myers, RM | 1 |
| Pistore, C | 1 |
| Giannoni, E | 1 |
| Colangelo, T | 1 |
| Rizzo, F | 1 |
| Magnani, E | 1 |
| Muccillo, L | 1 |
| Giurato, G | 1 |
| Mancini, M | 1 |
| Rizzo, S | 1 |
| Riccardi, M | 1 |
| Sahnane, N | 1 |
| Del Vescovo, V | 1 |
| Kishore, K | 1 |
| Mandruzzato, M | 1 |
| Macchi, F | 1 |
| Pelizzola, M | 1 |
| Denti, MA | 1 |
| Furlan, D | 1 |
| Weisz, A | 1 |
| Colantuoni, V | 1 |
| Chiarugi, P | 1 |
| Bonapace, IM | 1 |
| Storebjerg, TM | 1 |
| Strand, SH | 1 |
| Høyer, S | 1 |
| Lynnerup, AS | 1 |
| Borre, M | 1 |
| Ørntoft, TF | 1 |
| Sørensen, KD | 1 |
| Takayama, K | 1 |
| Misawa, A | 1 |
| Suzuki, T | 1 |
| Takagi, K | 1 |
| Hayashizaki, Y | 1 |
| Fujimura, T | 1 |
| Homma, Y | 1 |
| Takahashi, S | 1 |
| Urano, T | 1 |
| Inoue, S | 1 |
| Haffner, MC | 1 |
| Chaux, A | 1 |
| Meeker, AK | 1 |
| Esopi, DM | 1 |
| Gerber, J | 1 |
| Pellakuru, LG | 1 |
| Toubaji, A | 1 |
| Argani, P | 1 |
| Iacobuzio-Donahue, C | 1 |
| Nelson, WG | 1 |
| Netto, GJ | 1 |
| De Marzo, AM | 1 |
| Yegnasubramanian, S | 1 |
| Cortese, R | 1 |
| Kwan, A | 1 |
| Lalonde, E | 1 |
| Bryzgunova, O | 1 |
| Bondar, A | 1 |
| Wu, Y | 1 |
| Gordevicius, J | 1 |
| Park, M | 1 |
| Oh, G | 1 |
| Kaminsky, Z | 1 |
| Tverkuviene, J | 1 |
| Laurinavicius, A | 1 |
| Jankevicius, F | 1 |
| Sendorek, DH | 1 |
| Haider, S | 1 |
| Wang, SC | 1 |
| Jarmalaite, S | 1 |
| Laktionov, P | 1 |
| Boutros, PC | 1 |
| Petronis, A | 1 |
| Jacob, ST | 1 |
| Majumder, S | 1 |
| Ghoshal, K | 1 |
| Pakneshan, P | 1 |
| Xing, RH | 1 |
| Rabbani, SA | 2 |
| Lin, CC | 1 |
| Wu, HC | 1 |
| Tsai, FJ | 1 |
| Chen, HY | 1 |
| Chen, WC | 1 |
| Trzeciak, AR | 1 |
| Nyaga, SG | 1 |
| Jaruga, P | 1 |
| Lohani, A | 1 |
| Dizdaroglu, M | 1 |
| Evans, MK | 1 |
| Powell, IJ | 1 |
| Land, SJ | 1 |
| Dey, J | 1 |
| Heilbrun, LK | 1 |
| Hughes, MR | 1 |
| Sakr, W | 1 |
| Everson, RB | 1 |
| Hoffman, RM | 1 |
| Grove, KL | 2 |
| Guo, X | 1 |
| Liu, SH | 1 |
| Gao, Z | 1 |
| Chu, CK | 1 |
| Cheng, YC | 2 |
| Sarosdy, MF | 2 |
| Higdon, AL | 1 |
| Demoor, CA | 1 |
| Lievano, G | 1 |
| Di Domenico, D | 1 |
| Brown, J | 1 |
| Bridges, P | 1 |
| Rubenstein, M | 2 |
| Shaw, M | 2 |
| Guinan, P | 2 |
| Akaza, H | 1 |
| Ratanawong, S | 1 |
| Chou, P | 1 |
| Ray, V | 1 |
| Mirochnik, Y | 1 |
| Slobodskoy, L | 1 |
| Harakidas, P | 1 |
| Bowlin, T | 1 |
| Attardo, G | 1 |
| Steiner, M | 1 |
| Hillenbrand, M | 1 |
| Borkowsi, M | 1 |
| Seiter, H | 1 |
| Schuff-Werner, P | 1 |
| Tamada, H | 1 |
| Kitazawa, R | 1 |
| Gohji, K | 1 |
| Kitazawa, S | 1 |
| Singal, R | 1 |
| van Wert, J | 1 |
| Bashambu, M | 1 |
| Gourdeau, H | 1 |
| Clarke, ML | 1 |
| Ouellet, F | 1 |
| Mowles, D | 1 |
| Selner, M | 1 |
| Richard, A | 1 |
| Lee, N | 1 |
| Mackey, JR | 1 |
| Young, JD | 1 |
| Jolivet, J | 1 |
| Lafrenière, RG | 1 |
| Cass, CE | 1 |
| Gilbert, SM | 1 |
| Benson, MC | 1 |
| McKiernan, JM | 1 |
| Gelmann, EP | 1 |
| Bedford, MT | 1 |
| van Helden, PD | 1 |
3 reviews available for cytosine and Cancer of Prostate
| Article | Year |
|---|---|
[Development of new drugs for urological cancers].
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Renal Cell; | 1997 |
Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population.
Topics: Adenine; Black People; Cytosine; Guanosine; Humans; Linkage Disequilibrium; Male; Prostatic Neoplasm | 2002 |
Molecular biology of the androgen receptor.
Topics: Adenine; Animals; Cytosine; Guanine; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Risk; T | 2002 |
25 other studies available for cytosine and Cancer of Prostate
| Article | Year |
|---|---|
The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adenine; Androgens; Cytosine; Guanine; Humans; Male; Membrane | 2022 |
Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.
Topics: Adult; Aged; Biomarkers, Tumor; Cytosine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Huma | 2017 |
DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.
Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Transformation, Neoplastic; Culture Media, Con | 2017 |
Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
Topics: 5-Methylcytosine; Adult; Aged; Cytosine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regul | 2018 |
TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
Topics: 5-Methylcytosine; Aged; Androgens; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; | 2015 |
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers.
Topics: 5-Methylcytosine; Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Differe | 2011 |
Epigenetic markers of prostate cancer in plasma circulating DNA.
Topics: Aged; Biomarkers, Tumor; Case-Control Studies; Centromere; Chromosomes, Human, Pair 10; Cytosine; DN | 2012 |
Suppression of metallothionein-I/II expression and its probable molecular mechanisms.
Topics: Animals; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cytosine; DNA-Binding Proteins; | 2002 |
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
Topics: Animals; Base Sequence; Blotting, Southern; Cell Division; Cytosine; DNA Methylation; Gene Expressio | 2003 |
Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Cytosine; Endothelial Growth Factors; Genetic Markers; H | 2003 |
Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145.
Topics: Adenine; Antioxidants; Blotting, Western; Catalase; Cell Division; Cell Line, Tumor; Cell Nucleus; C | 2004 |
The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy.
Topics: Adenine; Age Factors; Aged; Black People; Cytosine; Disease Progression; Exons; Genotype; Guanine; H | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Colonic Neoplasms; Cytarab | 1995 |
In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cytosine; Male; Neoplasm Transplantation; Prostatic | 1996 |
Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line; Cytarabine; Cytosine; Dioxolanes; | 1996 |
Oral bropirimine immunotherapy of rodent prostate cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Cytosin | 1997 |
Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cytosine; Down-Regulation; Gene E | 1997 |
Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.
Topics: Animals; Antineoplastic Agents; Cell Division; Cytosine; Hydroxyquinolines; Immunohistochemistry; Ma | 1998 |
Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Division; Cytosine; Dioxolanes; Doxorubicin; Ma | 1998 |
609 C --> T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia.
Topics: Adenocarcinoma; Alleles; Cytosine; Female; Genes, Neoplasm; Genotype; Humans; Male; NAD(P)H Dehydrog | 1999 |
Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer.
Topics: Aged; Blotting, Northern; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 6; Bone Morphogen | 2001 |
Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells.
Topics: Azacitidine; Base Sequence; Cytosine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expressio | 2001 |
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Topics: Amino Acid Sequence; Antineoplastic Agents; Biological Transport; Carrier Proteins; Cytarabine; Cyti | 2001 |
Hypomethylation of DNA in pathological conditions of the human prostate.
Topics: 5-Methylcytosine; Adult; Aged; Aged, 80 and over; Cytosine; DNA; Humans; Male; Mathematics; Methylat | 1987 |